Patrys non-executive chair retires following completion of PAT-DX1 engineering, citing "new chapter" for the company – Proactive Investors Australia

by | Aug 9, 2022 | Engineer

10:30 Mon 08 Aug 2022
Patrys in period of development as it prepares first clinical trial program for deoxymab platform
“With the successful conclusion of the PAT-DX1 engineering run, it is now wholly appropriate that Patrys appoints a new chair for its next chapter as it focuses on becoming a clinical stage therapeutic antibody company,” Outoing chair John Read said.
Patrys Ltd (ASX:PAB)’s inaugural non-executive chair John Read will retire from his role as chair and director of the company, effective from Wednesday, August 31, 2022. Michael Stork (non-executive director) will take on the interim chair role as the company searches for someone with the correct expertise to fill the position.
“It has been an absolute privilege to be part of the Patrys leadership team since the company’s listing on the ASX in 2007,” the outgoing chair said.
“I am particularly proud of our progress in advancing the deoxymab platform in preparation for its first in human clinical trial planned for the second half of calendar year 2023.
“I am indebted to my fellow directors and Patrys’ CEO, Dr James Campbell, for their wisdom, professionalism and dedication.
“With the successful conclusion of the PAT-DX1 engineering run, it is now wholly appropriate that Patrys appoints a new chair for its next chapter as it focuses on becoming a clinical stage therapeutic antibody company.”
John Read guided the development of Patrys’ deoxymab antibody technology platform while working closely with CEO Dr James Campbell to expand the portfolio of clinical applications and partnerships for Patrys’ deoxymab technology.
“John has made a sustained and significant contribution to Patrys since his appointment as chair in May 2007,” Patrys CEO Dr James Campbell said.
“Patrys has transformed considerably under John’s stewardship, and he leaves the company in a strong position and with a clear trajectory to becoming a clinical-stage company.
“On a personal front, I am very grateful for John’s knowledge, support, expertise, wise counsel and guidance over the years.
“On behalf of the board, I would like to extend my heartfelt thanks to John and wish him every success in his future endeavours.”
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions,…
Patrys Ltd (ASX:PAB)’s James Campbell speaks with Proactive’s Elisha Newell about the company’s successful engineering run to produce large-scale quantities of clinical grade PAT-DX1. It Is believed that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas,…
Prev article
Next article
Only registered members can use this feature.
or
Copyright © Proactive Group Holdings Inc, 2022
All Rights Reserved – Proactive Australia PTY LTD ACN:132787654 ABN:19132787654.
Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which sections of the website you find most interesting and useful. See our Cookie Policy for more information.
Strictly Necessary and Functional
These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.
Advertising
Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.
Performance
Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.

source